利伐沙班应如何使用？

As the prevalence of venous thrombosis increases, drugs to treat it are also emerging. So why is it popular among people? In recent years, new anticoagulant drugs Factor Xa (FXa) inhibitors have received more and more attention among anticoagulant drugs, among which rivaroxaban is a representative drug of FXa inhibitors. Rivaroxaban is a small molecule oral anticoagulant jointly developed by Bayer and Johnson & Johnson, with the trade name Xarelto. Rivaroxaban is a highly selective, oral drug that directly inhibits factor xa. By inhibiting factor xa, the endogenous and exogenous pathways of the coagulation cascade can be interrupted, and the generation of thrombin and thrombosis can be inhibited. Xarelto does not inhibit thrombin and has no proven effect on platelets. A dose-dependent inhibition of factor xa activity by rivaroxaban has been observed in humans.

Let’s take a look at the usage and dosage of rivaroxaban.

The recommended dose is oral rivaroxaban 10 mg once daily. If the wound has stopped bleeding, the first medication should be administered between 6 and 10 hours after surgery. The length of treatment is determined by each patient's risk of VTE, i.e. by the type of orthopedic surgery the patient has undergone. For patients undergoing major hip surgery, a recommended course of treatment is 5 weeks. For patients undergoing major knee surgery, a recommended course of treatment is 2 weeks. If a dose is missed, the patient should take rivaroxaban immediately and continue taking it once daily the next day. Patients can take Xarelto with a meal or alone.

Rivaroxaban is available as red film-coated tablets. Its main active ingredient is: Rivaroxaban, a highly selective oral drug that directly inhibits factor Xa. Clinically indicated for the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its main mechanism of action is: inhibitory factor Xa can interrupt the endogenous and exogenous pathways of the coagulation cascade and inhibit the generation of thrombin and thrombosis.

Due to the pharmacodynamic properties of rivaroxaban, overdose may result in bleeding complications. At the same time, some subgroups of patients are at higher risk of bleeding, such as patients with liver damage and kidney damage. After initiation of treatment, these patients should be monitored closely for signs of bleeding complications.

The above is the content of the usage. We hope that patients must read the instructions clearly and use the medicine safely.